Literature DB >> 16814432

Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus (Herpes suid 1).

Daniel Dory1, Timo Fischer, Véronique Béven, Roland Cariolet, Hanns-Joachim Rziha, André Jestin.   

Abstract

The present study demonstrates the protective potential of a novel prime-boost vaccination strategy of pigs against lethal Pseudorabies virus (PRV; Herpes suid 1) infection. Animals were primed with Sindbis virus-derived plasmids that express viral glycoproteins gC and gD (gC- and gD-pSIN) and subsequently booster immunized with Orf virus (ORFV; Parapoxvirus) recombinants expressing gC and gD (D1701-VrVgC and -VrVgD). The prime-boost vaccination induced strong humoral and cellular-like PRV-specific immune responses. All prime-boost vaccinated pigs survived the lethal challenge infection without PRV-specific clinical symptoms and presented excellent body weight loss attenuation. Most notably, nasal shedding of challenge virus was reduced by more than about 3log(10), clearly reducing the risk of infection of non-immunized pigs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814432     DOI: 10.1016/j.vaccine.2006.05.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Cytokine protein expression levels in tracheobronchial lymph node homogenates of pigs infected with pseudorabies virus.

Authors:  Laura C Miller; Eraldo L Zanella; W Ray Waters; Kelly M Lager
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

2.  Limited protection conferred by a DNA vaccine against a lethal pseudorabies virus infection at day 5 postvaccination.

Authors:  Daniel Dory; Anne-Marie Torché; Véronique Béven; Roland Cariolet; André Jestin
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

3.  Orf virus (ORFV) ANK-1 protein mitochondrial localization is mediated by ankyrin repeat motifs.

Authors:  Krzysztof Lacek; Berthilde Bauer; Krystyna Bieńkowska-Szewczyk; Hanns-Joachim Rziha
Journal:  Virus Genes       Date:  2014-04-18       Impact factor: 2.332

4.  Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response.

Authors:  P O Ilyinskii; A B Meriin; V L Gabai; O P Zhirnov; G Thoidis; A M Shneider
Journal:  Vaccine       Date:  2008-03-14       Impact factor: 3.641

5.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 6.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

Review 7.  An overview of live attenuated recombinant pseudorabies viruses for use as novel vaccines.

Authors:  Bo Dong; Dante S Zarlenga; Xiaofeng Ren
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

8.  New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.

Authors:  Jörg Rohde; Ralf Amann; Hanns-Joachim Rziha
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

9.  Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus.

Authors:  Yuting Pan; Renyong Jia; Juping Li; Mingshu Wang; Shun Chen; Mafeng Liu; Dekang Zhu; Xinxin Zhao; Ying Wu; Qiao Yang; Zhongqiong Yin; Bo Jing; Juan Huang; Shaqiu Zhang; Lin Zhang; Yunya Liu; Yanlin Yu; Bin Tian; Leichang Pan; Mujeeb Ur Rehman; Anchun Cheng
Journal:  Virol J       Date:  2020-05-12       Impact factor: 4.099

10.  Orf Virus-Based Vaccine Vector D1701-V Induces Strong CD8+ T Cell Response against the Transgene but Not against ORFV-Derived Epitopes.

Authors:  Alena Reguzova; Michael Ghosh; Melanie Müller; Hanns-Joachim Rziha; Ralf Amann
Journal:  Vaccines (Basel)       Date:  2020-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.